Form 8-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): November 1, 2006
CONMED
CORPORATION
(Exact
name of registrant as specified in its charter)
| |
|
|
|
New
York
|
0-16093
|
16-0977505
|
|
(State
or other jurisdiction of
|
(Commission
|
(I.R.S.
Employer
|
|
incorporation
or organization)
|
File
Number)
|
Identification
No.)
|
525
French Road
Utica,
New York 13502
(Address
of principal executive offices, including zip code)
(315)
797-8375
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligations of the registrant under any of the following
provisions (See General Instruction A.2 below):
oWritten
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement; Item 5.02 Departure of
Principal Officers; Election of Directors; Appointment of Principal Officers
On
November 1, 2006, CONMED Corporation announced that its Board of Directors
has
elected Joseph J. Corasanti to be its next Chief Executive Officer, effective
January 1, 2007. He currently serves as President and Chief Operating Officer.
He will succeed Eugene R. Corasanti who will continue to serve as Chairman
of
the Board of Directors in the capacity of non-executive Chairman. Mr. Eugene
Corasanti will relinquish his executive functions at the Company on December
31,
2006, remaining employed by the Company as Vice Chairman.
Mr.
Eugene Corasanti is the founder of CONMED Corporation and has led its growth
from a start-up in the 1970’s to its present position as a leader in the medical
technology marketplace. Mr. Joseph Corasanti joined the Company in 1993 as
General Counsel and Vice President of Legal Affairs. He was elected to the
Board
of Directors in 1994. In 1998 he assumed the role of Executive Vice-President
and General Manager. In 1999 he was appointed to his present position of
President and Chief Operating Officer. He will remain a Director of the
Company.
Mr.
Joseph Corasanti will add the title of Chief Executive Officer effective January
1, 2007, in addition to his present title as President. He is also a member
of
the Board of Directors of II-VI, Inc. (Nasdaq: IIVI), a manufacturer of optical
and electro-optical components and devices for infrared, e-ray, gamma-ray,
telecommunication and other applications, where he also serves as a member
of
the audit committee. He holds a B.A. degree in Political Science from Hobart
College and a J.D degree from Whittier College School of Law. He is admitted
to
the state bar of both New York and California. Prior to joining CONMED
Corporation, he worked as a trial attorney in the Los Angeles office of Morgan
Wenzel and McNichols, a practice concentrating on business and civil
litigation.
Section
9
Financial
Statements and Exhibits
Item
9.01
Financial
Statements and Exhibits.
The
following exhibits are included herewith:
Exhibit
No.
Description
of Exhibit
| |
10.1
|
Amendment
No. 1 to November 12, 2004 Employment Agreement between the Company
and
Joseph J. Corasanti, dated October 31, 2006
|
| |
10.2
|
Employment
Agreement between the Company and Eugene R. Corasanti, dated October
31,
2006
|
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
CONMED
CORPORATION
|
| |
(Registrant)
|
| |
|
|
| |
By:
|
Robert D. Shallish, Jr
|
| |
|
Vice
President - Finance and
|
| |
|
Chief
Financial Officer
|
Date:
November
1, 2006